age at least 18 Years
Item
Alter mindestens 18 Jahre
boolean
397669002 (SNOMED CT 2011_0131)
C0001779 (UMLS CUI-1)
Chronic hepatitis C, HCV-genotype 2/3, HCV RNA and anti-HCV positive
Item
Male and female patients with HCV-genotype 2/3 chronic hepatitis C documented by detectable plasma HCV RNA (> 15 IU/mL) and positivity of anti-HCV antibodies
boolean
248153007 (SNOMED CT 2011_0131)
M (HL7 V3 2006_05)
248152002 (SNOMED CT 2011_0131)
F (HL7 V3 2006_05)
62944002 (SNOMED CT 2011_0131)
10019752 (MedDRA 14.1)
19338005 (SNOMED CT 2011_0131)
421291004 (SNOMED CT 2011_0131)
128302006 (SNOMED CT 2011_0131)
10008912 (MedDRA 14.1)
B18.2 (ICD-10-CM Version 2010)
439401001 (SNOMED CT 2011_0131)
MTHU008876 (LOINC Version 232)
50863008 (SNOMED CT 2011_0131)
MTHU002157 (LOINC Version 232)
121204002 (SNOMED CT 2011_0131)
MTHU001816 (LOINC Version 232)
10019747 (MedDRA 14.1)
C0524910 (UMLS CUI-1)
C0369335 (UMLS CUI-2)
C0281863 (UMLS CUI-3)
Compensated liver disease
Item
Compensated liver disease (Child-Pugh Grade A clinical classification)
boolean
17275008 (SNOMED CT 2011_0131)
235856003 (SNOMED CT 2011_0131)
10024670 (MedDRA 14.1)
K76.9 (ICD-10-CM Version 2010)
573.9 (ICD-9-CM Version 2011)
258349007 (SNOMED CT 2011_0131)
MTHU003112 (LOINC Version 232)
422097006 (SNOMED CT 2011_0131)
C0205432 (UMLS CUI-1)
C0023895 (UMLS CUI-2)
C4050412 (UMLS CUI-3)
C0441800 (UMLS CUI-4)
C1706281 (UMLS CUI-5)
Non-pregnant, effective contraception
Item
Negative urine or blood pregnancy test (one of the both, for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. Additionally, all fertile males and females must be using two forms of effective contraception during treatment and during the 7 months after treatment end. This includes using birth control pills (no interaction with investigational drugs), IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state. At least one contraception method must be of barrier method
boolean
224526002 (SNOMED CT 2011_0131)
167254001 (SNOMED CT 2011_0131)
10036577 (MedDRA 14.1)
166435006 (SNOMED CT 2011_0131)
248152002 (SNOMED CT 2011_0131)
F (HL7 V3 2006_05)
248153007 (SNOMED CT 2011_0131)
M (HL7 V3 2006_05)
146680009 (SNOMED CT 2011_0131)
10010808 (MedDRA 14.1)
59261009 (SNOMED CT 2011_0131)
268460000 (SNOMED CT 2011_0131)
10022745 (MedDRA 14.1)
20359006 (SNOMED CT 2011_0131)
10062116 (MedDRA 14.1)
76498008 (SNOMED CT 2011_0131)
225370004 (SNOMED CT 2011_0131)
C0043210 (UMLS CUI-1)
C1148523 (UMLS CUI-2)
C0237399 (UMLS CUI-3)
C0430057 (UMLS CUI-4)
C0430061 (UMLS CUI-5)
CL426012 (UMLS CUI-6)
C0086287 (UMLS CUI-7)
C0086582 (UMLS CUI-8)
C0700589 (UMLS CUI-9)
C0009905 (UMLS CUI-10)
C0021900 (UMLS CUI-11)
C0677582 (UMLS CUI-12)
C0042241 (UMLS CUI-13)
CL424925 (UMLS CUI-14)
C0038288 (UMLS CUI-15)
C0232970 (UMLS CUI-16)
C0004764 (UMLS CUI-17)
Current therapy with Peg-Interferon alpha-2b and ribavirin
Item
Ongoing treatment with 1.5 µg/kg Peg-Interferon alpha-2b (PegIntron) and > 10.6 mg/kg ribavirin (Rebetol)
boolean
395823000 (SNOMED CT 2011_0131)
387188005 (SNOMED CT 2011_0131)
MTHU018696 (LOINC Version 232)
C2827774 (UMLS CUI-1)
C0796545 (UMLS CUI-2)
C0035525 (UMLS CUI-3)
No rapid virological response
Item
No rapid virological response (HCV-RNA positive after week 4 of the ongoing therapy)
boolean
255358001 (SNOMED CT 2011_0131)
10019750 (MedDRA 14.1)
258705008 (SNOMED CT 2011_0131)
WK (HL7 V3 2006_05)
9362000 (SNOMED CT 2011_0131)
C1518422 (UMLS CUI-1)
C0456962 (UMLS CUI-2)
C1155328 (UMLS CUI-3)
Willingness to comply with study protocol
Item
Willingness to give written informed consent and willingness to participate to and to comply with the study protocol
boolean
C0021430 (UMLS CUI-4)
Ongoing pregnancy or breast feeding
Item
Women with ongoing pregnancy or breast feeding
boolean
224526002 (SNOMED CT 2011_0131)
289908002 (SNOMED CT 2011_0131)
10036556 (MedDRA 14.1)
MTHU035048 (LOINC Version 232)
10006247 (MedDRA 14.1)
C0032961 (UMLS CUI-1)
C0006147 (UMLS CUI-2)
Male partners of women who are pregnant
Item
Male partners of women who are pregnant
boolean
C0086582 (UMLS CUI 2011AA)
248153007 (SNOMED CT 2011_0131)
M (HL7 V3 2006_05)
C0682323 (UMLS CUI 2011AA)
262043009 (SNOMED CT 2011_0131)
SIGOTHR (HL7 V3 2006_05)
C0043210 (UMLS CUI 2011AA)
224526002 (SNOMED CT 2011_0131)
C0549206 (UMLS CUI 2011AA)
10036586 (MedDRA 14.1)
Positive tests for Hepatitis A/B/C, HIV
Item
Positive tests at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, HBeAg, anti-HIV, HIV-RNA
boolean
32609007 (SNOMED CT 2011_0131)
MTHU004541 (LOINC Version 232)
MTHU021816 (LOINC Version 232)
22290004 (SNOMED CT 2011_0131)
MTHU001814 (LOINC Version 232)
10052020 (MedDRA 14.1)
MTHU021816 (LOINC Version 232)
60605004 (SNOMED CT 2011_0131)
MTHU004548 (LOINC Version 232)
10002725 (MedDRA 14.1)
10049826 (MedDRA 14.1)
C1335447 (UMLS CUI-1)
C1409616 (UMLS CUI-2)
C0062524 (UMLS CUI-3)
C1442155 (UMLS CUI-4)
C0019168 (UMLS CUI-5)
C0948759 (UMLS CUI-6)
C1442155 (UMLS CUI-7)
C0019167 (UMLS CUI-8)
C0856918 (UMLS CUI-9)
C0877327 (UMLS CUI-10)
non-HCV chronic liver disease
Item
History or other evidence of a medical condition associated with chronic liver disease other than HCV associated (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures)
boolean
MEDCCAT (HL7 V3 2006_05)
328383001 (SNOMED CT 2011_0131)
10008953 (MedDRA 14.1)
62944002 (SNOMED CT 2011_0131)
10019752 (MedDRA 14.1)
399187006 (SNOMED CT 2011_0131)
10018872 (MedDRA 14.1)
E83.119 (ICD-10-CM Version 2010)
408335007 (SNOMED CT 2011_0131)
10003827 (MedDRA 14.1)
K75.4 (ICD-10-CM Version 2010)
571.42 (ICD-9-CM Version 2011)
41309000 (SNOMED CT 2011_0131)
10001627 (MedDRA 14.1)
K70.9 (ICD-10-CM Version 2010)
571.3 (ICD-9-CM Version 2011)
420239005 (SNOMED CT 2011_0131)
C1699700 (UMLS CUI-1)
C0341439 (UMLS CUI-2)
CL411789 (UMLS CUI-3)
C0220847 (UMLS CUI-4)
C0018995 (UMLS CUI-5)
C0241910 (UMLS CUI-6)
C0023896 (UMLS CUI-7)
C0040537 (UMLS CUI-8)
Bleeding from esophageal varices, decompensated liver disease
Item
History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
boolean
17709002 (SNOMED CT 2011_0131)
10030210 (MedDRA 14.1)
I85.01 (ICD-10-CM Version 2010)
456.0 (ICD-9-CM Version 2011)
E10682 (CTCAE 1105E)
260905004 (SNOMED CT 2011_0131)
COND (HL7 V3 2006_05)
385433004 (SNOMED CT 2011_0131)
10050060 (MedDRA 14.1)
C0155789 (UMLS CUI-1)
C0348080 (UMLS CUI-2)
C0332290 (UMLS CUI-3)
C0745744 (UMLS CUI-4)
Liver cirrhosis and suspected hepatic malignancy
Item
Patients with liver cirrhosis with a lesion suspicious for hepatic malignancy on the screening
boolean
19943007 (SNOMED CT 2011_0131)
10019641 (MedDRA 14.1)
K74.60 (ICD-10-CM Version 2010)
49755003 (SNOMED CT 2011_0131)
126851005 (SNOMED CT 2011_0131)
10019695 (MedDRA 14.1)
C22.0 (ICD-10-CM Version 2010)
C0023890 (UMLS CUI-1)
C0221198 (UMLS CUI-2)
C0242114 (UMLS CUI-3)
C0023903 (UMLS CUI-4)
C1409616 (UMLS CUI-5)
Neutropenia
Item
Absolute neutrophil count (ANC) <750 cells/mm3 at screening
boolean
10052033 (MedDRA 14.1)
C0948762 (UMLS CUI-1)
C1409616 (UMLS CUI-2)
Low platelet count
Item
Platelet count <50,000 cells/mm3 at screening
boolean
365632008 (SNOMED CT 2011_0131)
777-3 (LOINC Version 232)
C1287267 (UMLS CUI-1)
C1409616 (UMLS CUI-2)
Anemia
Item
Hb <10 g/dl at screening
boolean
38082009 (SNOMED CT 2011_0131)
10019481 (MedDRA 14.1)
LP14449-0 (LOINC Version 232)
C0019046 (UMLS CUI-1)
C1409616 (UMLS CUI-2)
Dose modification of Peg-Interferon alpha-2b or ribavirin
Item
Dose modification of Peg-Interferon alpha-2b (PegIntron) or ribavirin (Rebetol) during the first 4 weeks of the ongoing therapy
boolean
395823000 (SNOMED CT 2011_0131)
387188005 (SNOMED CT 2011_0131)
MTHU018696 (LOINC Version 232)
255216001 (SNOMED CT 2011_0131)
258706009 (SNOMED CT 2011_0131)
MO (HL7 V3 2006_05)
C1707811 (UMLS CUI-1)
C0796545 (UMLS CUI-2)
C0035525 (UMLS CUI-3)
C0205435 (UMLS CUI-4)
C0439231 (UMLS CUI-5)
C0039798 (UMLS CUI-6)
Previous therapy with Interferon alpha or ribavirin
Item
Interferon alpha or ribavirin therapy at any time point before the actual ongoing treatment
boolean
387188005 (SNOMED CT 2011_0131)
MTHU018696 (LOINC Version 232)
288556008 (SNOMED CT 2011_0131)
C1610033 (UMLS CUI-1)
C0035525 (UMLS CUI-2)
C0039798 (UMLS CUI-3)
C0332152 (UMLS CUI-4)
C0237400 (UMLS CUI-5)
C0039798 (UMLS CUI-6)
Low adherence to ongoing treatment
Item
< 80% adherence to treatment of the ongoing treatment until randomization (week 20-22 of ongoing treatment)
boolean
71978007 (SNOMED CT 2011_0131)
C0205412 (UMLS CUI-1)
C1171369 (UMLS CUI-2)
CL415091 (UMLS CUI-3)
C0034656 (UMLS CUI-4)
Serum creatinine elevated
Item
Serum creatinine level >1.5 times the upper limit of normal at screening
boolean
113075003 (SNOMED CT 2011_0131)
10040230 (MedDRA 14.1)
C0201976 (UMLS CUI-1)
C1519815 (UMLS CUI-2)
History of severe psychiatric disease, especially depression
Item
History of severe psychiatric disease, especially depression (ICD 10 codes F30-F33). Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time. Patients are excluded if any history of suicidal attempts is evident. If hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease are documented, psychiatric consultation is mandatory. Patients with a mild or moderate psychiatric disease (ICD 10 codes F32.0, F32.1, F33.0, F33.1) are only allowed to be included into the trial if a regular monitoring by a psychiatrist is performed during the trial
boolean
161464003 (SNOMED CT 2011_0131)
310497006 (SNOMED CT 2011_0131)
372720008 (SNOMED CT 2011_0131)
MTHU006782 (LOINC Version 232)
10784006 (SNOMED CT 2011_0131)
MTHU003337 (LOINC Version 232)
Z91.5 (ICD-10-CM Version 2010)
394656005 (SNOMED CT 2011_0131)
10054112 (MedDRA 14.1)
21134002 (SNOMED CT 2011_0131)
10013050 (MedDRA 14.1)
DIS (HL7 V3 2006_05)
74732009 (SNOMED CT 2011_0131)
10037174 (MedDRA 14.1)
F99 (ICD-10-CM Version 2010)
290-319.99 (ICD-9-CM Version 2011)
C0455498 (UMLS CUI-1)
C0588008 (UMLS CUI-2)
C0003289 (UMLS CUI-3)
C0040615 (UMLS CUI-4)
C2911479 (UMLS CUI-5)
C0019993 (UMLS CUI-6)
C1948053 (UMLS CUI-7)
C0231170 (UMLS CUI-8)
CL420107 (UMLS CUI-9)
C0004936 (UMLS CUI-10)
History of a severe seizure disorder or current anticonvulsant use
Item
History of a severe seizure disorder or current anticonvulsant use
boolean
CL421546 (UMLS CUI 2011AA)
392521001 (SNOMED CT 2011_0131)
C0852425 (UMLS CUI 2011AA)
10039912 (MedDRA 14.1)
C1524063 (UMLS CUI 2011AA)
260676000 (SNOMED CT 2011_0131)
C0003299 (UMLS CUI 2011AA)
255632006 (SNOMED CT 2011_0131)
MTHU006781 (LOINC Version 232)
History of immunologically mediated disease
Item
History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis)
boolean
392521001 (SNOMED CT 2011_0131)
64572001 (SNOMED CT 2011_0131)
47429007 (SNOMED CT 2011_0131)
116003000 (SNOMED CT 2011_0131)
MTHU013246 (LOINC Version 232)
24526004 (SNOMED CT 2011_0131)
10021972 (MedDRA 14.1)
32273002 (SNOMED CT 2011_0131)
10021245 (MedDRA 14.1)
D69.3 (ICD-10-CM Version 2010)
200936003 (SNOMED CT 2011_0131)
10025134 (MedDRA 14.1)
L93 (ICD-10-CM Version 2010)
695.4 (ICD-9-CM Version 2011)
413603009 (SNOMED CT 2011_0131)
10002046 (MedDRA 14.1)
283.0 (ICD-9-CM Version 2011)
89155008 (SNOMED CT 2011_0131)
10039710 (MedDRA 14.1)
24484000 (SNOMED CT 2011_0131)
9014002 (SNOMED CT 2011_0131)
10037153 (MedDRA 14.1)
L40 (ICD-10-CM Version 2010)
69896004 (SNOMED CT 2011_0131)
10039073 (MedDRA 14.1)
M06.9 (ICD-10-CM Version 2010)
714.0 (ICD-9-CM Version 2011)
CL421546 (UMLS CUI-1)
C0012634 (UMLS CUI-2)
C0332281 (UMLS CUI-3)
C0020962 (UMLS CUI-4)
C0021390 (UMLS CUI-5)
C0398650 (UMLS CUI-6)
C0409974 (UMLS CUI-7)
C0002880 (UMLS CUI-8)
C0011644 (UMLS CUI-9)
C0205082 (UMLS CUI-10)
C0033860 (UMLS CUI-11)
C0003873 (UMLS CUI-12)
History or any other evidence of autoimmune diseases
Item
History or any other evidence of autoimmune diseases
boolean
CL421546 (UMLS CUI 2011AA)
392521001 (SNOMED CT 2011_0131)
C0205394 (UMLS CUI 2011AA)
74964007 (SNOMED CT 2011_0131)
C0004364 (UMLS CUI 2011AA)
85828009 (SNOMED CT 2011_0131)
10061664 (MedDRA 14.1)
M30-M36 (ICD-10-CM Version 2010)
E11258 (CTCAE 1105E)
Chronic pulmonary disease
Item
History or other evidence of chronic pulmonary disease associated with functional limitation
boolean
392521001 (SNOMED CT 2011_0131)
18669006 (SNOMED CT 2011_0131)
413839001 (SNOMED CT 2011_0131)
47429007 (SNOMED CT 2011_0131)
40143009 (SNOMED CT 2011_0131)
246175000 (SNOMED CT 2011_0131)
CL421546 (UMLS CUI-1)
C0332120 (UMLS CUI-2)
C0746102 (UMLS CUI-3)
C0332281 (UMLS CUI-4)
C0205245 (UMLS CUI-5)
C0449295 (UMLS CUI-6)
History of significant cardiac disease
Item
History of significant cardiac disease that could be worsened by acute anemia (e.g. NYHA Functional Class III or IV, myocardial infarction within 6 months prior to treatment with Peg-Interferon/ribavirin therapy, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina)
boolean
392521001 (SNOMED CT 2011_0131)
56265001 (SNOMED CT 2011_0131)
10061024 (MedDRA 14.1)
420913000 (SNOMED CT 2011_0131)
10064081 (MedDRA 14.1)
422293003 (SNOMED CT 2011_0131)
10064082 (MedDRA 14.1)
22298006 (SNOMED CT 2011_0131)
10028596 (MedDRA 14.1)
MTHU035551 (LOINC Version 232)
I21-I22 (ICD-10-CM Version 2010)
410 (ICD-9-CM Version 2011)
E10152 (CTCAE 1105E)
288556008 (SNOMED CT 2011_0131)
387188005 (SNOMED CT 2011_0131)
MTHU018696 (LOINC Version 232)
25569003 (SNOMED CT 2011_0131)
10065341 (MedDRA 14.1)
I47.2 (ICD-10-CM Version 2010)
E10239 (CTCAE 1105E)
4557003 (SNOMED CT 2011_0131)
10002388 (MedDRA 14.1)
I20.0 (ICD-10-CM Version 2010)
411.1 (ICD-9-CM Version 2011)
CL421546 (UMLS CUI-1)
C0018799 (UMLS CUI-2)
C1319795 (UMLS CUI-3)
C1319796 (UMLS CUI-4)
C0027051 (UMLS CUI-5)
C0332152 (UMLS CUI-6)
C0982327 (UMLS CUI-7)
C0035525 (UMLS CUI-8)
C0039798 (UMLS CUI-9)
C0042514 (UMLS CUI-10)
C0002965 (UMLS CUI-11)
Poorly controlled thyroid disease
Item
Evidence of thyroid disease that is poorly controlled on prescribed medications
boolean
14304000 (SNOMED CT 2011_0131)
10043709 (MedDRA 14.1)
E00-E07 (ICD-10-CM Version 2010)
240-246.99 (ICD-9-CM Version 2011)
556001 (SNOMED CT 2011_0131)
31509003 (SNOMED CT 2011_0131)
C0040128 (UMLS CUI-1)
C0205169 (UMLS CUI-2)
C2587213 (UMLS CUI-3)
C0013227 (UMLS CUI-4)
Severe retinopathy
Item
Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration)
boolean
24484000 (SNOMED CT 2011_0131)
399625000 (SNOMED CT 2011_0131)
10038923 (MedDRA 14.1)
E10432 (CTCAE 1105E)
22455005 (SNOMED CT 2011_0131)
10011835 (MedDRA 14.1)
422338006 (SNOMED CT 2011_0131)
10025409 (MedDRA 14.1)
MTHU020821 (LOINC Version 232)
C0205082 (UMLS CUI-1)
CL365148 (UMLS CUI-2)
C0206178 (UMLS CUI-3)
C0024437 (UMLS CUI-4)
Major organ transplantation
Item
History of major organ transplantation with an existing functional graft
boolean
392521001 (SNOMED CT 2011_0131)
255603008 (SNOMED CT 2011_0131)
10061890 (MedDRA 14.1)
MTHU000173 (LOINC Version 232)
40143009 (SNOMED CT 2011_0131)
24486003 (SNOMED CT 2011_0131)
CL421546 (UMLS CUI-1)
C0205164 (UMLS CUI-2)
C0029216 (UMLS CUI-3)
C0205245 (UMLS CUI-4)
C0332835 (UMLS CUI-5)
Severe illness
Item
History or other evidence of severe illness, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
boolean
24484000 (SNOMED CT 2011_0131)
39104002 (SNOMED CT 2011_0131)
10040658 (MedDRA 14.1)
R69 (ICD-10-CM Version 2010)
363346000 (SNOMED CT 2011_0131)
10028997 (MedDRA 14.1)
MTHU010328 (LOINC Version 232)
C00-C96 (ICD-10-CM Version 2010)
260905004 (SNOMED CT 2011_0131)
COND (HL7 V3 2006_05)
23981006 (SNOMED CT 2011_0131)
116154003 (SNOMED CT 2011_0131)
110465008 (SNOMED CT 2011_0131)
C0205082 (UMLS CUI-1)
C0221423 (UMLS CUI-2)
C0006826 (UMLS CUI-3)
C0348080 (UMLS CUI-4)
C0678227 (UMLS CUI-5)
C0030705 (UMLS CUI-6)
C1548788 (UMLS CUI-7)
C0008976 (UMLS CUI-8)
Systemic anti-neoplastic or immunomodulatory treatment
Item
History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
boolean
392521001 (SNOMED CT 2011_0131)
31099001 (SNOMED CT 2011_0131)
116566001 (SNOMED CT 2011_0131)
CL421546 (UMLS CUI-1)
C0205373 (UMLS CUI-2)
C0920425 (UMLS CUI-3)
CL412323 (UMLS CUI-4)
C0038317 (UMLS CUI-5)
C0034619 (UMLS CUI-6)
Tuberculosis
Item
Patients with evidence for tuberculosis
boolean
18669006 (SNOMED CT 2011_0131)
56717001 (SNOMED CT 2011_0131)
10044755 (MedDRA 14.1)
MTHU020835 (LOINC Version 232)
A15-A19 (ICD-10-CM Version 2010)
010-018.99 (ICD-9-CM Version 2011)
C0041296 (UMLS CUI-1)
Drug abuse
Item
Drug abuse within 6 months prior to the first dose of study drug and excessive alcohol consumption. Patients on methadone/polamidone/buprenorphine programs are not excluded
boolean
26416006 (SNOMED CT 2011_0131)
10013654 (MedDRA 14.1)
LP36310-8 (LOINC Version 232)
305.90 (ICD-9-CM Version 2011)
160592001 (SNOMED CT 2011_0131)
E (HL7 V3 2006_05)
51758009 (SNOMED CT 2011_0131)
MTHU001002 (LOINC Version 232)
31684002 (SNOMED CT 2011_0131)
MTHU006723 (LOINC Version 232)
C0013146 (UMLS CUI-1)
C0560219 (UMLS CUI-2)
C1554961 (UMLS CUI-3)
C0025605 (UMLS CUI-4)
C0006405 (UMLS CUI-5)
Participation in another clinical study
Item
Any investigational drug and/or participation in another clinical study prior 6 months to the actual ongoing antiviral treatment
boolean
74964007 (SNOMED CT 2011_0131)
PART (HL7 V3 2006_05)
74964007 (SNOMED CT 2011_0131)
110465008 (SNOMED CT 2011_0131)
288556008 (SNOMED CT 2011_0131)
68244004 (SNOMED CT 2011_0131)
258706009 (SNOMED CT 2011_0131)
MO (HL7 V3 2006_05)
C0205394 (UMLS CUI-1)
C0013230 (UMLS CUI-2)
C0679823 (UMLS CUI-3)
C0205394 (UMLS CUI-4)
C0008976 (UMLS CUI-5)
C0332152 (UMLS CUI-6)
C0205452 (UMLS CUI-7)
C0439231 (UMLS CUI-8)
Limited contractual capability
Item
Limited contractual capability
boolean
C0439801 (UMLS CUI 2011AA)
255469002 (SNOMED CT 2011_0131)
C0332522 (UMLS CUI 2011AA)
CNTRCT (HL7 V3 2006_05)
C2698977 (UMLS CUI 2011AA)